---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-014414"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:54:36.040057+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics withdraws Translarna NDA resubmission after FDA cites insufficient efficacy data

## Summary
- Withdrew NDA resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy.
- FDA feedback indicated data unlikely to meet substantial evidence of effectiveness threshold.
- CEO Matthew Klein expressed disappointment after more than two decades of development efforts.
- No path to FDA approval for Translarna in the U.S. at this time.
- PTC Therapeutics (PTCT) shares potential negative impact from this regulatory setback.

## SEC filing metadata
- accession: 0001104659-26-014414
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465926014414/0001104659-26-014414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465926014414/tmb-20260212x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-014414
- JSON: https://secwatch.observer/filing/0001104659-26-014414.json
- Plain text: https://secwatch.observer/filing/0001104659-26-014414.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.